共 50 条
Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE Study
被引:0
|作者:
Teixeira, Maria Margarida
[1
]
Dias, Joao
[2
]
Andre, Teresa
[3
]
Joaquim, Ana
[4
]
Fernandes, Ricardo
[5
]
Magalhaes, Joana
[6
]
Marreiros, Laura
[7
]
Pinto, Leonor
[8
]
Ribeiro, Leonor
[9
]
Nogueira, Mafalda
[10
]
Morais, Catarina
[10
]
机构:
[1] Inst Portugues Oncol Coimbra Francisco Gentil, P-3000075 Coimbra, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, P-4200072 Porto, Portugal
[3] Hosp Dr Nelio Mendonca, P-9000177 Funchal, Portugal
[4] Unidade Local Saude Gaia Espinho, P-4434502 Vila Nova De Gaia, Portugal
[5] Unidade Local Saude Braga, P-4710243 Braga, Portugal
[6] Unidade Local Saude Algarve, P-8000386 Faro, Portugal
[7] Unidade Local Saude Almada Seixal, P-2805267 Almada, Portugal
[8] Unidade Local Saude Coimbra, P-3004561 Coimbra, Portugal
[9] Unidade Local Saude Santa Maria, P-1649035 Lisbon, Portugal
[10] MSD Portugal, Paco De Arcos, Portugal
关键词:
head and neck;
recurrent or metastatic disease;
real-world;
healthcare resources;
patient management;
SQUAMOUS-CELL CARCINOMA;
GUIDELINES(R) INSIGHTS HEAD;
RECURRENT/METASTATIC HEAD;
PEMBROLIZUMAB;
CHEMOTHERAPY;
EPIDEMIOLOGY;
KEYNOTE-048;
CETUXIMAB;
RISK;
D O I:
10.3390/curroncol31080318
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50-69 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (>70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.
引用
收藏
页码:4270 / 4283
页数:14
相关论文